Glial Fibrillary Acidic Protein Human ELISA (GFAP)

Cat. No.	Size	Price
RD192072200R	96 wells (1 kit)	$711

Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cerebrospinal fluid

Sample Requirements

35 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.25–25 ng/ml

Limit of Detection

0.045 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 5.1%

Inter-assay (Run-to-Run)

n = 7; CV = 5.7%

Spiking Recovery

102,90%

Dilution Linearity

100,60%

Crossreactivity

bovine Not tested
cat Not tested
dog Not tested
goat Not tested
hamster Not tested
horse Not tested
human Not tested
chicken Not tested
monkey Not tested
mouse Not tested
pig Not tested
rabbit Not tested
rat Not tested
sheep Not tested

Summary

Features

It is intended for research use only
The total assay time is about 5 hours
The kit measures GFAP in serum, cerebrospinal fluid (CSF) and plasma
Assay format is 96 wells
Quality Controls are human serum based
Standard is purified native protein based
Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Neural tissue markers

Summary

Glial Fibrillary Acidic Protein (GFAP), as a member of the cytoskeletal protein family, is the principal 8-9 nm intermediate filament in mature astrocytes of the central nervous system (CNS). GFAP is a monomeric molecule with a molecular mass between 40 and 53 kDa and an isoelectric point between 5.7 and 5.8. GFAP is highly brain specific protein that is not found outside the CNS. Some studies showed that GFAP is released into the blood very soon after traumatic brain injury (TBI), that GFAP is related to brain injury severity and outcome after TBI and that GFAP is not released after multiple trauma without brain injury.

In the CNS following injury, either as a result of trauma, disease, genetic disorders, or chemical insult, astrocytes become reactive and respond in a typical manner, termed astrogliosis. Astrogliosis is characterized by rapid synthesis of GFAP. GFAP normally increases with age and there is a wide variation in collection and processing of human brain tissue. Thanks to the high brain specificity and early releasing from CNS after TBI, GFAP might be suitable marker for early diagnostics.

Areas of investigation: Brain injury, Ischemic stroke.

Product References (33)

References

Summary References (11)

References to Glial Fibrillary Acidic Protein

Runnerstam M et al.: Extracellular glial fibrillary acidic protein and amino acids in brain regions of patients with subarachnoid hemorrhage – correlation with level of consciousness and site of bleeding. Neurolofical Research. 19: 361–368 (1997)
Missler U et al.: Measurement of glial fibrillary acidic protein in human blood: analytical method and premiliary clinical results. Clinical Chemistry. 45(1): 138–41 (1999)
Eng LF et al.: Glial fibrillary acidic protein: GFAP – Thirty – One Years (1969–2000). Neurochemical Research. 25: 1439–1451 (2000)
Whitelaw A et al.: Brain specific proteins in postheamorrhagic ventricular dilatation. Arch Dis Child Fetal Neonatal Ed. 84: F90-F91 (2001)
Finch CE: Neurons, Glia, and Plasticity in normal Brain Aging. Adv Gerontol. 10: 35–39 (2002)
Beems T et al.: Serum- and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochirurgica. 145: 37–43 (2003)
Pelinka LE et al.: Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. Journal of Trauma. 57: 1006–1012 (2004)
Pelinka LE et al.: GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome. Journal of Neurotrauma. 21: 1553–1561 (2004)
Mouser PE et al.: Caspase-Mediated Cleavage of Glial Fibrillary Acidic Protein within Degenerating Astrocytes of the Alzheimer’s Disease Brain. Am J Pathol. 168(3): 936– 946 (2006)
Blechingberg J et al.: Regulatory mechanisms for 3'-end alternative splicing and polyadenylation of the Glial Fibrillary Acidic Protein, GFAP, transcript. Nucleic Acids Res. 35(22): 7636–50 (2007)
Brommeland T et al.: Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand. 116(6): 380–4 (2007)

By Research Topic